Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 6/2018

01-06-2018 | Letter to the Editor

Re: Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment

Authors: Kelsea Caruso, Michele Kanter

Published in: International Journal of Hematology | Issue 6/2018

Login to get access

Excerpt

Direct-oral anticoagulant toxicities are generally associated with bleeding complications, but other adverse effects can also occur. Porru et al. report an interesting case of a patient with dabigatran toxicity presenting with acute liver and renal injury [1]. The authors, however, fail to include some important details when evaluating patients with potential dabigatran toxicity. …
Literature
1.
Porru M, Mameli A, Cianchetti ME, Musu M, Schirru P, Ruberto MF, et al. Dabigatran overdose: a case report of acute hepatitis, dabigatran case report. Extracorporeal treatment. Int J Hematol. 2017;105:532–5.CrossRefPubMed
2.
Praxbind (package insert). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; 2015.
Metadata
Title
Re: Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment
Authors
Kelsea Caruso
Michele Kanter
Publication date
01-06-2018
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 6/2018
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-018-2418-2

Other articles of this Issue 6/2018

International Journal of Hematology 6/2018 Go to the issue

Original Article

miR-150 regulates B lymphocyte in autoimmune hemolytic anemia/Evans syndrome by c-Myb

Guide Line

Chinese guidelines for treatment of adult primary immune thrombocytopenia

Progress in Hematology

The hematopoietic stem cell diet

Case Report

Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia

Case Report

10-year complete remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient using imatinib without high-intensity chemotherapy or allogeneic stem cell transplantation

Original Article

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR–ABL kinase domain mutations
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits